Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium Tc 99m butedronate
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
technetium Tc 99m butedronate (commonly known as 99mTc-DPD) is a technetium-99m-labeled bisphosphonate radiopharmaceutical used as a diagnostic imaging agent. It is primarily utilized in bone scintigraphy to detect areas of altered osteogenesis, such as bone metastases, osteomyelitis, and other skeletal disorders. Additionally, 99mTc-DPD is highly effective and widely used in cardiac scintigraphy for the non-invasive diagnosis of transthyretin cardiac amyloidosis (ATTR-CA), where it binds to calcium-rich microcalcifications associated with amyloid deposits in the myocardium. The drug is marketed under the brand name Teceos by Curium.
- Brand names
- Teceos
- Other names
- 99mTc-2,3-dicarboxypropane-1,1-diphosphonate99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid99mTc-DPD99mTc-butedronate99mTc-dicarboxypropane diphosphonatebutedronate tetrasodiumtechnetium (99mTc) butedronatetechnetium Tc 99m 2,3-dicarboxypropane-1,1-diphosphonatetechnetium Tc 99m butedronate
Beyond the preview
Go deeper on technetium Tc 99m butedronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium Tc 99m butedronate.